The digital revolution is an amazing opportunity to innovate in Ophtalmology. Taking into account that the electronic technologies are 2 times cheaper and 2 times more powerful every 2 years, this impacts several fields such as power of calculation, sensors and networks, robotics and nanotechnology, extended reality, artificial intelligence, biosciences. We can already see the emergence of MEMS (Micro Electro Mechanical Systems), sensors combining mechanics and electronics in order to connect the physical world to the digital. The sight is not forgiven, and

Fabrice MERCIER Medtech Director; Head of Alliance Management +33 6 10 40 60 56 fabrice.mercier@theaopeninnovation.com www.theaopeninnovation.com www.laboratoires-thea.com the development of MEMS to other physical senses could be inspiring for the ophthalmic world, with the benefits for both the patient and the healthcare professionals. Such king of digital technology can offer better tracking, educational tools, personalized coaching and consequently, bring more quietude to the patient, while it can allow refocusing on primary mission to the healthcare professional. Théa Open Innovation is a subsidiary of the Théa group, leading independent European pharmaceutical company specialized in the research, development, and commercialization of eye-care products. Théa Open Innovation’s mission is to enrich Théa's R&D pipeline with innovative therapeutic products in ophthalmology, led by biotech, medtech and digital companies. We select the most promising candidates and invest in their co-development through licensing agreements. Our partners retain their specific expertise in-house and remain the leaders of their projects while benefiting from Théa's financing and know-how in ophthalmology.

Organized in collaboration with Business France